MPP4 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q96JB8 |
---|
Gene ID | 58538 |
---|---|
Other Names | MAGUK p55 subfamily member 4, Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 5 protein, Discs large homolog 6, MPP4, ALS2CR5, DLG6 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | MPP4 |
---|---|
Synonyms | ALS2CR5, DLG6 |
Function | May play a role in retinal photoreceptors development. |
Cellular Location | Cytoplasm. Note=Detected at the outer limiting membrane (OLM) and in the outer plexiform layer (OPL) of the retina. At the OLM, detected apical to the adherens junction (AJ) |
Tissue Location | Expressed in the retina (at protein level). Highly expressed in the retina. Lower amounts are detected in brain, testis, ARPE-19, RPE/choroid and fetal eye. Isoform 5 is retina-specific |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
MPP4 encodes a member of the membrane-associated guanylate kinase (MAGUK) protein family, with an N-terminal PDZ domain, a central src homology 3 region (SH3), and a C-terminal guanylate kinase-like (GUK) domain. The protein is localized to the outer limiting membrane in the retina, and is thought to function in photoreceptor polarity and the organization of specialized intercellular junctions.
References
Voss, M., et al. BMC Immunol. 10, 53 (2009) Kantardzhieva, A., et al. Invest. Ophthalmol. Vis. Sci. 46(6):2192-2201(2005)Stohr, H., et al. J. Comp. Neurol. 481(1):31-41(2005)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.